ReviewCancer prevention research (Philadelphia, Pa.)2015
The antigenic repertoire of premalignant and high-risk lesions.
Review in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Advances in mRNA vaccine therapy for breast cancer research.Discover oncology · 2025Review
- Preservation of antigen-specific responses in cryopreserved CD4Journal of translational autoimmunity · 2022Article
- Vaccines for Non-Viral Cancer Prevention.International journal of molecular sciences · 2021Review
- AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health.Cancer prevention research (Philadelphia, Pa.) · 2018Article
- The dawn of vaccines for cancer prevention.Nature reviews. Immunology · 2018Review
- Cancer Prevention: Lessons Learned and Future Directions.Trends in cancer · 2016Review
- Clinical significance of tumor-infiltrating lymphocytes in breast cancer.Journal for immunotherapy of cancer · 2016Review
- The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- The Promise of Preventive Cancer Vaccines.Vaccines · 2015Review
- Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Prophylactic vaccines have been a major advance in preventing the development of infections after exposure to pathogens. When contemplating an effective approach to cancer prevention, vaccines offer unique advantages over other more standard approaches: First, once appropriately stimulated, antigen-specific T cells will travel to all sites of disease and eradicate cells bearing the proteins to which the T cells have been primed by vaccination. Second, successful immunization will further result in the development of immunologic memory, providing lifelong immunologic surveillance. There is evidence of an adaptive tumor immune infiltrate even at the earliest stages of breast and colon cancer development. Furthermore, there is measurable immunity to lesion-associated antigens present in patients who will eventually develop malignancy even before cancer is clinically evident. Recent studies are beginning to unmask the preinvasive antigenic repertoire for these two malignancies. Preliminary experiments in transgenic mouse models of mammary and intestinal tumors suggest that immunization against antigens expressed in preinvasive and high-risk lesions may be effective in preventing the development of invasive malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.